Jared Whitlock is a Features Editor at Endpoints News. He focuses on federal legislation, drugs and medication, and health news, providing insightful coverage on these critical topics. Jared has been featured in Endpoints News, highlighting his expertise in the intersection of health policy and pharmaceutical developments.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
Not enough data
Jared Whitlock's coverage primarily revolves around legal and compliance issues within the healthcare, pharmaceutical, and biotechnology industries. He also focuses on private sector announcements and government announcements related to these sectors.
To effectively reach out to Jared, experts in legal matters related to healthcare and biotechnology would be valuable sources for commentary or analysis of industry-specific regulations. Professionals with insights into corporate governance, M&A activities, executive appointments/departures within pharmaceutical or biotech companies could also provide relevant perspectives.
As his geographic focus is not specified but given the nature of his articles which often involve US-based companies such as Illumina, focusing on developments within the United States in relation to regulatory changes or specific company actions may be particularly relevant when reaching out to him.
This information evolves through artificial intelligence and human feedback. Improve this profile .
By: Jared Whitlock
Hepta Bio has developed a test that’s designed to diagnose the liver disease MASH from a blood draw, potentially reducing the need for invasive biopsies.
By: Jared Whitlock
Features Editor China will reverse its ban on importing DNA sequencers from Illumina, the company confirmed on Wednesday, potentially marking a renewed business opportunity in a key …
By: Jared Whitlock
Features Editor Top FDA officials on Wednesday sketched out a new regulatory approach that aims to keep pace with scientific advances in personalized medicine. It builds off …
By: Jared Whitlock
Features Editor WuXi AppTec's reprieve from a Washington crackdown may not last. The Pentagon has reportedly concluded WuXi AppTec should be added to a list of companies …
By: Gene Tx
Nationwide Children's gene therapy shows early promise after Taysha pullback Features Editor
By: Jared Whitlock
A softened version of the Biosecure Act has moved closer to final passage in Congress, but the bill could still shift US biopharma supply chains …
Features Editor A diluted form of the Biosecure Act appears close to becoming law, after the House on Wednesday approved a defense bill that includes the measure …
By: Jared Whitlock
China's new commercial insurance formulary looks to expand patient access to Alzheimer's disease medicines from Eli Lilly and Eisai while potentially boosting revenue for the …
By: Jared Whitlock
Features Editor Boston-based company Cellens secured $6.5 million to develop its platform that detects bladder cancer through an approach that combines physics and AI, Endpoints News learned …
By: Jared Whitlock
Features Editor Eric Green, a pioneering geneticist and former NIH director, is slated to become the chief medical officer of the genomics giant Illumina, Endpoints News learned …
